TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Preventive service receipt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Arterial Pressure Changes During Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HR Changes During Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The Grade of Coughing During Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival (PFS) at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Functional capacity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence With Recommended Supine Sleep Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence With Recommended Roomsharing Without Bed Sharing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence With Recommended Pacifier Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence With Recommended Avoiding Use of Soft Bedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Brain Gray Matter Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression-free disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free peritoneal cancer cells (FPCCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in KOOS Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IKDC Subjective Knee Evaluation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optical density of macular pigment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Striae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in startle reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on key questions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bone Turnover Marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Myocardial biopsy results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Histologic liver injury progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lung mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence rate of corneal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of days in the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: quantitative measurement of plasma IL-1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Breathing swallowing interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of adverse events related to therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Clinical Worsening Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hypoglycemias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Concentration of Adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choice of insulin treatment regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: KOOS pain subdomain score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Any, Grade 3, Related and Grade 3 and Related Unsolicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: mean number of flares per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Face emotion recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From 0 to Infinity (AUC0-inf) of Elbasvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Elbasvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-Life (t1/2) of Elbasvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity and specificity of amblyopia risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival of allergen-specific effector T cells
Endpoint domain: Mortality/survival
Primary endpoint: Change of Perceived Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in MDS-UPDRS part III (OFF) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in subjective symptoms of total score related to vaginal discomfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of composite events of infection
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of composite events of hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of composite events of perforation
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of composite events of pancreatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants in the Interventional Phase Who Achieved LDA and Discontinued Oral GC Within 20 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain assessed by the Brief Pain Inventory Interference Scale (BPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain severity measured by Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain measured by Biberoglu and Behrman patient ratings scale (B&B pain scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Quality of Life (EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in number of uNK/CD56 cells per field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time required to use COR-KNOT vs. Standard Suture Tying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with Clinical Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue bound AGE level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Determination of the Maximum Tolerated Dose (MTD) by Number of Subjects With DLTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center for Epidemiological Studies Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Revised Memory and Behavior Problems Checklist
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in diastolic and systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glucose Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glaucoma Medication Percent Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Glaucoma Medication Adherence Self-Efficacy Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: New Infection With Mycobacterium Tuberculosis
Endpoint domain: Adverse events/effects
Primary endpoint: lung-metastases free survival
Endpoint domain: Mortality/survival
Primary endpoint: Recession depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total soft tissue gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Village-specific ocular chlamydia among 0-5 children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ocular chlamydia among 8-12 year olds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incident ocular chlamydia in 0-5 year-olds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pharmacokinetics of panobinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cormack & Lehane score without maneuver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cormack & Lehane score with maneuver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight change in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in central corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of amphiregulin plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotypic characterization of gut Treg cells and CD8+ T lymphocytes (CTL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Study of fibrosis markers in the intestinal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cmax - maximum observed plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax - time at which Cmax occurs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ - area under the plasma concentration-time curve from time zero to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse and Cardiac Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Severity of Psychotic Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Social Functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Time to Culture Conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to accept treatment attributes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reliability of measurement tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of decitabine
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical activity of decitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Blood Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Therapy Completers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum NT-proBNP value change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of FEV1 after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite GHP outcomes health score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Histological performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in the Clinical Global Impression of Severity (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hamilton Depression Rating Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of suspected and documented mold infection
Endpoint domain: Adverse events/effects
Primary endpoint: Intestinal microbiota domination by healthcare associated pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Classified as Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Reporting Spectacle Independence at All Distances
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Vision-Related Quality of Life as Reported on the NEI-RQL 42 (5 Dimensions)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mid-arm circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ponderal Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Absolute Change of Serum Ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Pupil Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or recurrent myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Severe hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Weekly Average Nocturnal Symptom Scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change From Baseline in Weekly Average Daily (24 Hour) Sputum Volume Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Pulse Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antral follicle count (AFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Responder rates based on disease-related health status improvements
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Regional lung volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Level of satisfaction with EVRA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with flattening of PED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Anterior Chamber Cell Grade 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Unterberga Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sternocleidomastoid muscle tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Longus Colli muscle tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mediterranean Diet Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety labs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Total Nasal Symptom Score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective response to alcohol
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients receiving pharmacological sedation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Passing flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Self-reported Consistent Condom Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sexual Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intimacy
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Patient reported back pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in the Right Ventricle (RV) Diameter-to-Left Ventricle (LV) Diameter Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Major Bleeding Within 72 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Prefrontal GABA+ Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prefrontal Glx Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of BCI as a switch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacteremia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Occlusion of the stent or artificial blood vessel bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: WOMAC Pain Subscale Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological complete response rate (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % Body fat levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Regional GABA and glutamate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: UPDRS III motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta in E/e' at rest exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aliskiren Concentrations From Interstitial Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amlodipine Concentrations From Interstitial Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiotensin II Levels in Interstitial Fluid of Fat and Skeletal Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with One or More Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with One or More Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Discontinued from the Study due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change on Neurohormonal Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on Left Ventricular Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-breakfast glucose exposure (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of novel PET tracer for CB1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Proliferation Rate (Ki-67)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acute Bronchiolitis Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of immediate glucose tolerance testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of menstrual cycle pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes